See more : Spyglass Resources Corp. (SGLRF) Income Statement Analysis – Financial Results
Complete financial analysis of Zogenix, Inc. (ZGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- TPCO Holding Corp. (GRMWF) Income Statement Analysis – Financial Results
- Hywin Holdings Ltd. (HYW) Income Statement Analysis – Financial Results
- TG Venture Acquisition Corp. (TGVCW) Income Statement Analysis – Financial Results
- Grand Industrial Holding Co., Ltd. (000626.SZ) Income Statement Analysis – Financial Results
- Bank Polska Kasa Opieki S.A. (BKPKF) Income Statement Analysis – Financial Results
Zogenix, Inc. (ZGNX)
About Zogenix, Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.69M | 13.64M | 3.65M | 0.00 | 9.82M | 28.85M | 27.18M | 40.53M | 33.01M | 44.33M | 37.58M | 23.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.83M | 542.00K | 0.00 | 0.00 | 10.73M | 22.47M | 22.70M | 31.88M | 22.48M | 20.85M | 20.50M | 13.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.86M | 13.10M | 3.65M | 0.00 | -908.00K | 6.38M | 4.48M | 8.65M | 10.53M | 23.48M | 17.08M | 9.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 94.08% | 96.03% | 100.00% | 0.00% | -9.25% | 22.12% | 16.49% | 21.35% | 31.89% | 52.96% | 45.45% | 41.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.66M | 138.00M | 115.64M | 100.93M | 67.45M | 41.84M | 27.86M | 18.94M | 12.81M | 21.41M | 33.04M | 28.64M | 21.44M | 33.91M | 24.33M | 4.90M |
| General & Administrative | 0.00 | 99.57M | 33.63M | 23.22M | 21.12M | 20.99M | 22.41M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Selling & Marketing | 0.00 | 0.00 | 27.17M | 15.73M | 4.76M | 6.00M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 148.52M | 99.57M | 60.79M | 38.95M | 25.89M | 27.00M | 26.35M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Other Expenses | 7.89M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 10.00K |
| Operating Expenses | 299.07M | 241.52M | 176.43M | 139.88M | 93.33M | 68.84M | 54.21M | 107.84M | 62.85M | 70.91M | 93.50M | 79.91M | 35.54M | 45.73M | 29.05M | 6.38M |
| Cost & Expenses | 303.90M | 242.06M | 176.43M | 139.88M | 104.06M | 91.30M | 76.91M | 139.71M | 85.33M | 91.76M | 114.00M | 93.60M | 35.54M | 45.73M | 29.05M | 6.38M |
| Interest Income | 659.00K | 2.89M | 9.80M | 7.17M | 1.09M | 443.00K | 0.00 | 20.00K | 18.00K | 53.00K | 37.00K | 5.00K | 10.00K | 696.00K | 0.00 | 0.00 |
| Interest Expense | 15.28M | 3.76M | 2.00K | 6.00K | 2.64M | 2.83M | 0.00 | 3.09M | 6.61M | 10.31M | 7.64M | 10.01M | 9.19M | 1.72M | 1.35M | 980.00K |
| Depreciation & Amortization | 9.46M | 5.47M | 1.27M | 155.00K | 425.00K | 1.40M | 1.62M | 1.63M | 1.81M | 1.60M | 1.58M | 1.43M | 5.31M | 1.10M | 410.00K | 1.96M |
| EBITDA | -202.58M | -217.58M | -418.23M | -123.75M | -123.75M | -66.43M | 11.86M | 13.39M | -72.44M | -35.47M | -74.68M | -62.11M | -31.39M | -42.75M | -25.92M | -4.42M |
| EBITDA Ratio | -247.98% | -1,594.84% | -11,464.72% | 0.00% | -1,260.03% | -230.25% | 43.65% | 33.03% | -219.44% | -80.02% | -198.75% | -264.96% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -212.03M | -247.72M | -429.82M | -141.18M | -119.94M | -72.69M | -47.73M | -20.04M | -53.19M | -47.43M | -76.42M | -70.16M | -35.54M | -45.73M | -29.05M | -6.38M |
| Operating Income Ratio | -259.56% | -1,815.71% | -11,782.37% | 0.00% | -1,221.22% | -251.94% | -175.58% | -49.44% | -161.13% | -107.00% | -203.39% | -299.29% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.28M | 20.91M | 10.32M | 17.46M | -6.09M | 3.05M | -9.88M | 28.71M | -27.66M | 50.00K | -7.49M | -3.39M | -1.17M | 1.18M | 1.37M | 980.00K |
| Income Before Tax | -227.31M | -226.81M | -419.50M | -123.72M | -126.02M | -69.63M | -57.61M | 8.67M | -80.86M | -47.38M | -83.91M | -73.55M | -36.71M | -44.55M | -27.68M | -5.40M |
| Income Before Tax Ratio | -278.26% | -1,662.45% | -11,499.53% | 0.00% | -1,283.19% | -241.37% | -211.92% | 21.39% | -244.93% | -106.89% | -223.31% | -313.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 105.00K | -17.43M | 10.32M | 17.47M | -3.44M | -948.00K | -15.90M | 84.00K | -21.05M | 5.00K | -9.00K | 10.00K | 8.02M | 2.90M | 2.72M | 0.00 |
| Net Income | -227.41M | -209.38M | -419.50M | -123.91M | -126.82M | -69.71M | 26.14M | 8.59M | -80.86M | -47.39M | -83.90M | -73.56M | -45.89M | -45.57M | -27.68M | -5.40M |
| Net Income Ratio | -278.39% | -1,534.73% | -11,499.53% | 0.00% | -1,291.28% | -241.62% | 96.18% | 21.19% | -244.93% | -106.90% | -223.29% | -313.81% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.48 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| EPS Diluted | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.47 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| Weighted Avg Shares Out | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 17.83M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
| Weighted Avg Shares Out (Dil) | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 18.13M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
New FINTEPLA® (Fenfluramine) Data Show Long-Term Seizure Frequency Reductions in Patients with Lennox-Gastaut Syndrome (LGS)
EMERYVILLE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data from an interim analysis of an on-going 12-month Phase 3 open-label extension (OLE) study (Study 1601; Part 2)...
Zogenix (ZGNX) Moves 6.2% Higher: Will This Strength Last?
Zogenix (ZGNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zogenix Reports Granting of Inducement Awards
EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to fourteen (14) new employees. The awards were made on September 15, 2021, under Zogenix's...
3 Biotech Stocks Wall Street Expects to Double Soon
All three stocks on this list can more than double your money according to investment bank analysts who cover them.
3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023
These fast-paced companies should generate jaw-dropping revenue growth over the next three years.
Zogenix Reports Granting of Inducement Awards
EMERYVILLE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to fourteen new employees. The awards were made on August 15, 2021, under Zogenix's 2021 Employment...
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q2 2021 Results - Earnings Call Transcript
Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q2 2021 Results - Earnings Call Transcript
Recap: Zogenix Q2 Earnings
Shares of Zogenix (NASDAQ:ZGNX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 9.38% year over year to ($1.05), which missed the estimate of ($0.94).
Zogenix to Participate in the BofA Securities SMID Cap 2H21 Ideas Conference
EMERYVILLE, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Chief Financial Officer, will participate in a virtual...
Source: https://incomestatements.info
Category: Stock Reports
What were Zogenix’s revenue and net loss in 2021?
Net loss for the second quarter ended June 30, 2021, was $58.9 million, or a net loss of $1.05 per share compared with a net loss of $53.3 million, or a net loss of $0.96 per share, in the second quarter ended June 30, 2020. The Company recorded $32.5 million in revenue for the six months ended June 30, 2021.